EZH2 and acute myeloid leukemia: EZH2 inhibitors, EPZ-6438 and GSK2816126, for instance, showed anti-neoplastic activity in acute myeloid leukemia (AML) and are currently in clinical trials of lymphoma treatment (Table 2).